Inovio Pharmaceuticals CEO Named “Entrepreneur of the Year” By Ernst & Young

Dr. J. Joseph Kim Selected for Philadelphia Region Award

PLYMOUTH MEETING, Pa. – June 12, 2015 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that Inovio’s Chief Executive Officer, Dr. J. Joseph Kim, has been selected as the “Entrepreneur of the Year™” for Greater Philadelphia by Ernst & Young, a global leader in assurance, tax, and advisory services.

Dr. Kim, who co-founded the organization that became Inovio Pharmaceuticals, was recognized for his vision, passion, medical and financial acumen in building Inovio from a two-person start-up into a clinical-stage publicly traded immunotherapy company with innovative therapies for cancers and infectious diseases.

Last year, Inovio reported a medical breakthrough by demonstrating the first clinically meaningful efficacy results from T cells generated exclusively in vivo in the history of its DNA based immunotherapy technology. These results were from a phase II study treating cervical pre-cancer. Early next year, Inovio will move this lead product into phase III. The company has also received more than $70 million in government grants in the past eight months to develop HIV, influenza and Ebola treatments and vaccines.

Dr. Kim said, "I thank Ernst & Young for this honor and for the input from family,friends, employees and business advisors who supported me and my vision to build a company that is striving to create safe and effective immunotherapies to help patients and their families beat cancer.” E&Y’s Entrepreneur of the Year is the world’s most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur of the Year celebrates those who are building and leading successful, growing and dynamic businesses.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline.

Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.